Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK NRT segment smokin’

This article was originally published in The Tan Sheet

Executive Summary

Nicotine replacement therapy sales advanced 14% "with all regions contributing to growth" to lead 2% OTC segment increase in the second quarter, GSK announces July 27. The firm is looking to future OTC weight-loss drug Xenical, which it acquired from Roche July 19 for $100 mil., to mirror success of smoking cessation products. Consumer Healthcare sales reached $1.44 bil., a 4% increase compared to the year-ago period; domestic sales were flat, although international sales rose 9% and European markets advanced 4%...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS097113

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel